Neurodiscovery Ltd operates in the Commercial physical research sector. NeuroDiscovery Limited (NeuroDiscovery) is a speciality neuroscience company. It is engaged in the development of compounds for the treatment of pain, and provision of specialized electrophysiology services to the biopharmaceutical industry. Electrophysiology is a specialized technique which is used to record electrical activity in membranes, cells or tissues. It operates in two segments: contract services, which provide research expertise on specialized electrophysiology assays to the biopharmaceutical industry, and research and development, engaged in the development of compounds for the treatment of pain. It owns interest in two programmes for the treatment of pain: NSL-101and NSL-043. It has identified NSL-101 from the United Kingdom-based Ampika Limited's database of medicinal plants as a natural product formulation that is effective in alleviating the symptoms of pain. During the fiscal year ended June 30, 2010, it disposed its wholly owned subsidiary NeuroSolutions Limited. In our complete report available for purchase the company is compared to: BKM Management Limited, Energio Limited and ECI Incorporation.